Plain-English translation of NCT07038356 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether patients hospitalized with acute heart failure should continue taking empagliflozin (a medication they're already using) during their hospital stay, or whether it's safer to pause it temporarily. The research team wants to understand if keeping patients on this medication helps prevent serious complications like death, additional hospitalizations, or kidney problems within 90 days of hospital admission.
When people with heart failure are hospitalized with severe fluid buildup, doctors aren't sure whether patients should keep taking their regular heart medications or temporarily stop them. This trial aims to answer that question and make sure patients get the safest possible care during this critical time.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to either take the study medication or a placebo (dummy tablet) daily while in the hospital—for up to 30 days. After you go home, you'll continue taking the actual medication once daily through day 90. Throughout the first week, you'll measure and record your urine output and track your fluid intake. You'll also complete brief questionnaires about how you're feeling at the hospital, when you're discharged, and at day 30.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Germany